ILT3-Binding Antibodies Block Immune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies face challenges in effectively targeting and modulating the immune response, particularly in cancer immunosurveillance, where cancer cells often evade immune recognition by hijacking inhibitory mechanisms, leading to suppressed immune activity and tumor growth.
Innovation Solution
Development of ILT3-binding agents, such as antibodies that specifically bind to immunoglobulin-like transcript 3 (ILT3), which inhibit ILT3 activity, restore immune cell function, and enhance immune responses by blocking ILT3-induced suppression of myeloid cells and promoting chemokine production, thereby reactivating immune cells like dendritic cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunotherapies are used to treat cancer, then immune response modulation is attempted, but cancer cells evade immune recognition by hijacking inhibitory mechanisms leading to suppressed immune activity
Solution Approach 1:
The patent employs ILT3-binding agents (antibodies) as intermediary molecules that specifically bind to ILT3 receptors on myeloid cells, blocking the interaction between ILT3 and its ligands. This intermediary approach prevents the harmful inhibitory signaling while preserving other immune functions, thereby resolving the contradiction between attempting immune modulation and avoiding ILT3-mediated suppression.
Solution Approach 2:
The invention converts the harmful ILT3 inhibitory mechanism into a therapeutic target. By specifically binding to ILT3 and blocking its suppressive function, the antibody transforms the cancer cells' evasion mechanism into a recognizable target for immune therapy, turning the harmful inhibitory pathway into a benefit for immune activation against tumors.
2Reliability
If ILT3-binding agents are administered, then immune suppression is inhibited and chemokine production is enhanced, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent focuses on targeting a specific segment of the immune system - the ILT3 receptor on myeloid cells - rather than attempting broad immune modulation. This segmented approach allows for precise inhibition of the harmful ILT3 pathway while leaving other immune mechanisms intact, thereby restoring immune cell function without requiring complex multi-target therapies.
Solution Approach 2:
The invention changes the functional parameter of ILT3 receptors by introducing high-affinity binding agents that alter the receptor's signaling state. By changing the binding parameter (from ligand-bound inhibitory state to antibody-bound blocked state), the therapy achieves reliable immune function restoration through a relatively simple mechanism of parameter modification rather than complex system restructuring.
Data Source
AI summary
The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.